Crystal Bio completed a $50 million round A financing

, an ophthalmology biotechnology company dedicated to the development of innovative therapies worldwide, Jingjing Biopharmaceutical Technology (Suzhou) Co., Ltd., has announced the completion of a $50 million round of financing. The financing was co-led by Lilly Asia Fund, Gao Yu Ventures and Quancheng Capital. Located in Suzhou Industrial Park, the company has a business center in Shanghai and plans to establish an international clinical and registration center in the San Francisco Bay Area."We are very grateful for the support and trust of the three internationally renowned investment institutions," said Dr. Jinzhong Zhang, co-founder, chairman and chief executive officer. The company will use the funds to build a globally innovative research and development pipeline and a core eye drug innovation technology platform to meet the medical needs of patients in China and around the world for eye diseases. At the same time, we are pleased to have three internationally renowned ophthalmologists, Professor Quan Dong Nguyen of Stanford University, Professor Liu Motherland of Xiamen University and Professor Sun Xiaodong of Shanghai Jiaozhou University, as members of the first Scientific Advisory Committee on Crystal Biology, and thank them for their advice and assistance in developing the company's strategy and research and development pipeline. Theis co-founded by Lilly Asia Fund and two Sea Returns. Dr. Jinzhong Zhang is a Ph.D. in Science jointly trained by Peking University and Kyoto University in Japan, an assistant professor of ophthalmology at Case Western Reserve University School of Medicine in the United States and a principal researcher in a project funded by the Institute of Ophthalmology of the National Institutes of Health. Dr. Hu, who has received his undergraduate and doctorate degrees in pharmacy from The University of Pharmacy in China and the University of Michigan in the United States, has been focusing on the field of ophthalmology for more than two decades and has extensive experience in the development, clinical needs, international regulations, technology transfer and market analysis of ophthalmology products at home and abroad.The company also announced that Dr. Charles Semba was invited to join The Crystal Biology as Chief Medical Officer. Dr. Seinpo is an internationally renowned specialist in the development of new ophthalmology drugs and has previously served as Chief Medical Officer of three ophthalmology companies: SARcode Bioscience (acquired by Shire / Takeda), ForSight VISION5 (acquired by Aljian) and Graybug Vision (NASDAQ: GRAY). He also served as Vice President of Ophthalmology at Shire / Takeda and Head of Ophthalmology Clinical Development at Gegentech. Dr. Sempo successfully led the clinical development of the world's first heavy antibody drug, LUCENTIS, to treat wet age-related macular lesions, and the first new dry eye drug XIIDRA, which simultaneously improves symptoms and signs.The company's core team also includes two accomplished members in ophthalmology translation medicine and clinical management. Dr. Shen Weiyong is a trained ophthalmologist in China and Australia, serving as Vice President of Research at Crystal Biology, where he has over 25 years of experience in basic and translational research in retinal diseases and has published more than 90 papers in the fields of ophthalmology and neuroscience. Dr. Li Mei is The Vice President of Clinical Operations at Jingjing Bio, and she has more than 20 years of experience in clinical trial management in China, where she has made important contributions to the clinical research and registration of several imported ophthalmology products in Eljian (China).Regarding the successful round A financing, all parties expressed confidence and expectations for the new company. Professor Liu said: "There are still many treatments for eye diseases around the world that do not meet the needs of patients, on the one hand, there is a need to carry out vigorous basic research to find out the pathogenesis of the disease, but also the need to find new drugs." The company has a strong drug development team, focusing on the development of innovative drugs in ophthalmology, which will promote the development of innovative drugs in ophthalmology in China, bringing good news and hope to ophthalmology patients. Lin, partner of Lilly Asia Fund, said: "We are honored to have the opportunity to co-found The Crystal Bio with Dr. Zhang Jinzhong and Dr. Hu Jinze. The team brings together a number of international and local innovative eye drug development elites, whose outstanding research and development experience has led us to believe that the company can develop innovative therapies not only for China but also for the global market. We are pleased to work with this experienced team and the industry's leading investment institutions from the outset to create a crystalline creature. With the company's take-off, we look forward to the crystallization of life can become the field of innovative eye medicine, the finishing touch. "With the increasing aging, lifestyle changes, excessive eye use and public health awareness, the incidence of eye diseases in China has been on the rise in recent years, however, the incidence of eye drug research and development technology requirements are high, and domestic approval of new drugs is less, domestic patients have a large number of unsuperfected demand," said Yi Noqing, co-chief investment officer ofThe founding team of Jingjing Bio has a wealth of drug development capabilities and continuous innovation capabilities, with great potential for the future. Gao will help the company continue to innovate, research and develop leading ophthalmological disease treatments to meet the unseeded needs of a large number of patients, and continuously create social well-being. Dr , Managing Director of Quancheng Capital, said: "Quancheng Capital is committed to bringing much-needed emerging therapies to patients by promoting innovation. We are pleased to co-lead the A-round financing of Crystal Bio, and we have been impressed by the company's excellent management team. We believe that this experienced team will become a leader in ophthalmology by accelerating the development of innovative therapies, both globally and in China. Quancheng Capital looks forward to working closely with Crystal Bio using resources in China and around the world. Founded in February 2020Eluminex Biosciences Limited is a biopharmaceutical company focused on ophthalmological diseases. Led by an experienced team, the company aims to establish innovative and sustainable pipelines of eye medicine products to address unsympathetic clinical needs and benefit patients with eye diseases in China and around the world. The company's headquarters and research and development center are located in Suzhou Industrial Park, with a business center in Shanghai, and plans to establish an international clinical and registration center in the San Francisco Bay Area. For more information, please contact john.hu@eluminexbio.com Hu Jinze via the website.

about Lilly AsiaLilly Asia Ventures is a leading biomedical venture capital firm with offices in Shanghai, Hong Kong and Silicon Valley, USA, in 2008. Its vision is to be a trusted partner for outstanding entrepreneurs seeking capital to build great companies and develop breakthrough products that can treat diseases and improve human health. Please visit for more information.About GaoXuan Venture CapitalGao Gao Ventures is a venture capital fund focused on early-stage innovative companies, focusing on biomedicine and medical devices, software and hard technology, consumer Internet and technology, emerging consumer brands and services in the four major areas of venture capital. The field of biomedicine and medical devices has been the key investment direction of Gao, which has invested more than 200 outstanding biomedical, medical device and medical services enterprises for more than a decade. Hope to work with enterprises, time friends, and jointly promote the innovation and development of large health enterprises, benefit more patients.

about Quancheng CapitalQuantron Capital is a venture capital fund focused on life sciences in the early and early stages of growth. Find, create, and invest in fast-growing life sciences leaders around the world, driven by innovation and guided by unique scientific and commercial insights. Companies in its portfolio include cutting-edge innovative therapies, cutting-edge technology platforms, and industry leaders who can fill gaps in the ecosystem. Quancheng Capital currently has offices in Shanghai, San Francisco and Boston. With a wealth of industry experience and deep industry resources, its professional investors identify and incubate the next generation of outstanding companies, and do their best to support the strategy, operation and development of emerging pharmaceutical technology companies, in the global support of different stages of development of the company transformation, to help the company to maximize value. Please visit for more information. (Biological exploration)